Author

Craig Hanis

The University of Texas Health Science Center at Houston

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Approach:statistical model· 1 Research Focus:variant effect prediction· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Adolfo CorreaiD· 1 shared Andre FrankeiD· 1 shared Andrea SaltzmaniD· 1 shared Anne O’Donnell‐LuriaiD· 1 shared Arcturus Wang· 1 shared Ben WeisburdiD· 1 shared Benjamin GläseriD· 1 shared Benjamin M. NealeiD· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenomics

Adolfo CorreaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Evaluating potential drug targets through human loss-of-function genetic variation

Eric Vallabh Minikel, Konrad J. Karczewski, Hilary C. Martin, Beryl B. Cummings, Nicola Whiffin, Daniel Rhodes, Jessica Alföldi, Richard C. Trembath, David A. van Heel, Mark J. Daly, Genome Aggregation Database Production Team, Irina M. Armean, Eric Banks, Louis Bergelson, Kristian Cibulskis, , Craig Hanis

The paper evaluates potential drug targets using loss-of-function genetic variants from gnomAD, highlighting the importance of deep curation and targeted recall studies for drug discovery.

Nature · May 27, 2020Peer-reviewedGenomics